The latest breakthrough Mounjaro, a drug based on tirzepatide, has produced stunning results for keeping off weight. This major – and exciting – finding comes from a new research study presented at the recent European Congress on Obesity (ECO) taking place in Malaga, Spain. The studies indicated that a weekly injection of this drug produces impressive and long-lasting weight loss. This effect is particularly pronounced among adults with overweight or obesity who do not have diabetes.
The study followed those participants over the course of their weight loss for up to 176 weeks. This model revealed three unique classes, which corresponded well to the various weight loss patterns. Group 1 continued to lose weight, ending the study still averaging a weight loss of almost 10% of their initial body weight. Group 2, consisting of 226 individuals, had quick early weight loss. They all achieved this remarkable reduction of upwards of 20% of their body weight before experiencing some kind of plateau. Of the 3 groups, Group 3, comprised of 226 people, had the highest candida diet weight loss, about 30% over time. They delayed in arriving at their plateau.
Jordan Hill, MCD, RD, CSSD, noted that the most important takeaway from the study was that people respond differently to treatment. He put emphasis into acknowledging weight loss plateaus.
“Also, it showed that individuals respond differently and there can be periods of weight loss plateaus. We also see weight loss plateaus in surgical weight loss patients,” – Mir Ali, MD.
Researchers quantified the time needed for study participants to reach a 20 percent loss in weight. As expected, these findings revealed a higher percent of females and those with no obesity-related health conditions in Group 3. In the subsequent three years, they hit the mark with an extraordinary 20% improvement on their results.
According to Alliance member Mir Ali, MD, with long-term use, Mounjaro can help patients achieve and maintain healthy weight loss.
“I thought this was a good study showing that these medications are very effective for substantial weight loss,” – Mir Ali, MD.
The SURMOUNT-1 trial showed unprecedentedly exciting results. In adults taking tirzepatide for 72 weeks, average weight loss ranged from 15% to 21% of participants’ initial body weight, based on the dosage they administered. The research finds that even a very modest amount of weight loss — as little as 5% — can significantly lower your risk of developing diabetes. It improves cardiovascular health in a big way. Greater reductions of around 15% are associated with even greater health benefits.
Hill went on to underscore the importance of medical intervention to help people manage their weight if they have been diagnosed with prediabetes.
“This research supports the idea of medical intervention and therapeutic approaches to managing weight in those with prediabetes,” – Jordan Hill.
He underscored the need to maintain medication for optimum outcomes. He understood the reality of weight loss plateaus and the difficulties they can impose.
“Each person responds differently, and it is important to continue these medications long term. There is a tendency for patients to get discouraged when they encounter weight loss plateaus,” – Mir Ali, MD.
Leave a Reply